Dr. Moskowitz on the ALCANZA Trial in CTCL
4 vistas
• 08/09/23
0
0
Empotrar
administrator
Suscriptores
Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios